How does colistin cause acute kidney injury?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mechanism of Colistin-Induced Acute Kidney Injury

Colistin causes AKI through multiple direct cellular injury mechanisms, primarily involving mitochondrial dysfunction, apoptosis via three major pathways (mitochondrial, death receptor, and endoplasmic reticulum), and more recently identified zinc dyshomeostasis-triggered pyroptosis, with nephrotoxicity being dose-dependent and likely reversible if detected early.

Primary Pathophysiologic Mechanisms

The nephrotoxicity of colistin operates through several interconnected cellular injury pathways:

Direct Tubular Toxicity

Colistin directly damages proximal tubular epithelial cells, which is where the drug accumulates after glomerular filtration. The most recent mechanistic evidence 1 demonstrates that colistin induces intracellular zinc ion overload in renal tubular epithelial cells, leading to zinc dyshomeostasis. This zinc accumulation augments gasdermin D (GSDMD)-executed pyroptosis—a proinflammatory programmed cell death pathway—thereby accelerating AKI progression.

Multiple Apoptotic Pathways

Earlier mechanistic studies 2 established that colistin-induced nephrotoxicity involves all three major apoptosis pathways simultaneously:

  • Mitochondrial pathway: Downregulation of anti-apoptotic Bcl-2 and upregulation of pro-apoptotic factors (cytochrome C and Bax), leading to mitochondrial dysfunction
  • Death receptor pathway: Upregulation of Fas, FasL, and Fas-associated death domain (FADD)
  • Endoplasmic reticulum stress pathway: Upregulation of Grp78/Bip, ATF6, GADD153/CHOP, and caspase-12

These pathways converge to activate executioner caspases (caspase-3, -8, and -9), resulting in DNA fragmentation, PARP-1 cleavage, and ultimately tubular cell death.

Oxidative Stress

Colistin generates significant oxidative stress in renal tissue, evidenced by increased malondialdehyde levels and decreased activities of protective antioxidant enzymes (superoxide dismutase and catalase) 2. This oxidative damage contributes to the formation of 8-hydroxydeoxyguanosine (8-OHdG), a marker of oxidative DNA damage.

Proximal Tubule Brush Border Damage

Research 3 reveals that colistin causes marked reduction in sodium-glucose transporter 2 (SGLT2) protein expression at the proximal tubule brush border membrane. This manifests clinically as renal glycosuria, which appears as an early marker of colistin-induced kidney damage even before conventional markers like serum creatinine become elevated.

Dose-Dependent Relationship

The FDA drug label 4 explicitly states that nephrotoxicity is "probably a dose-dependent effect of colistimethate sodium." Pharmacokinetic/toxicodynamic analysis 5 demonstrates that AKI rates are substantially higher when average steady-state plasma colistin concentrations exceed approximately 2 mg/liter. Clinical studies 6 show that daily colistin doses >4.5 mg/kg/day (adjusted to ideal body weight) significantly increase AKI risk.

Clinical Manifestations and Reversibility

The FDA label 4 emphasizes that manifestations of nephrotoxicity are reversible following discontinuation of the antibiotic. However, the severity varies:

  • AKI develops in 29-68.5% of patients receiving colistin 7, 6
  • Median time to AKI onset is 5-6 days after initiation 7, 6
  • Nephrotoxicity is reversed in approximately 87.5% of AKI patients who survive to hospital discharge 8
  • Approximately 7-50.8% of patients require renal replacement therapy 7, 9

Key Risk Factors

Multiple studies identify consistent risk factors that amplify colistin's nephrotoxic potential:

  • Age ≥75 years 8
  • Pre-existing chronic kidney disease 8
  • Baseline elevated creatinine 9
  • Concomitant vasopressor use 9, 8—this is one of the strongest independent predictors
  • Concomitant nephrotoxic drugs (aminoglycosides, vancomycin, NSAIDs) 4, 7, 9
  • Hypoalbuminemia 9, 8
  • Diuretic use 9
  • Duration of therapy ≥7 days 8

Clinical Monitoring Imperatives

Guidelines 10 provide a strong recommendation (1C) that renal function should be monitored during colistin treatment. The FDA label 4 warns that "impaired renal function increases the possibility of apnea and neuromuscular blockade," making monitoring critical for both nephrotoxicity and neurotoxicity prevention.

Early signs of impaired renal function include 4:

  • Diminishing urine output
  • Rising BUN and serum creatinine
  • Decreased creatinine clearance
  • Glycosuria (novel early marker) 3
  • Elevated urinary Kim-1 3

Important Clinical Caveats

The guidelines 10 acknowledge that acute kidney injury during and after colistin treatment is one of the most important factors related to clinical failure and mortality. Colistin-induced AKI independently predicts mortality (HR 1.74) 6, and all-cause mortality is significantly higher in patients who develop AKI (76.8% vs 29.4% in those without AKI) 8.

However, the FDA label 4 warns that colistin should not be withheld in life-threatening infections due to concern for AKI, as the benefit of treating multidrug-resistant infections often outweighs the nephrotoxicity risk. The key is balancing benefits and harms through careful patient selection, dose optimization, avoidance of concomitant nephrotoxins, and vigilant monitoring.

The 2015 ICU guidelines 11 note that polymyxin B may be associated with lower incidence of renal failure compared to colistin, offering an alternative when appropriate.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.